Left Ventricular Lead Placement Guided by Reduction in QRS Area

Mohammed Ali Ghossein 1,*, Francesco Zanon 2, Floor Salden 3, Antonius van Stipdonk 3, Lina Marcantoni 2, Elien Engels 4, Justin Luermans 3, Sjoerd Westra 5, Frits Prinzen 1 and Kevin Vernooy 3,5

1 Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6229 ER Maastricht, The Netherlands; frits.prinzen@maastrichtuniversity.nl
2 Santa Maria Della Misericordia General Hospital, 45100 Rovigo, Italy; franc.zanon@iol.it (F.Z.); lina.marcantoni@gmail.com (L.M.)
3 Maastricht University Medical Center, Department of Cardiology, Maastricht University, 6229 HX Maastricht, The Netherlands; floor.salden@mumc.nl (F.S.); twan.van.stipdonk@mumc.nl (A.v.S.); justin.luermans@mumc.nl (J.L.); kevin.vernooy@mumc.nl (K.V.)
4 Yale New Haven Hospital, New Haven, CT 06510, USA; elienengels@gmail.com
5 Radboud University Medical Center, Radboud University Nijmegen, 6525 GA Nijmegen, The Netherlands; sjoerd.westra@radboudumc.nl
* Correspondence: mohammed.ghossein@mumc.nl

Abstract: Background: Reduction in QRS area after cardiac resynchronization therapy (CRT) is associated with improved long-term clinical outcome. The aim of this study was to investigate whether the reduction in QRS area is associated with hemodynamic improvement by pacing different LV sites and can be used to guide LV lead placement. Methods: Patients with a class Ia/IIa CRT indication were prospectively included from three hospitals. Acute hemodynamic response was assessed as the relative change in maximum rate of rise of left ventricular (LV) pressure (%ΔLVdP/dtmax). Change in QRS area (ΔQRS area), in QRS duration (ΔQRS duration), and %ΔLVdP/dtmax were studied in relation to different LV pacing locations within a patient. Results: Data from 52 patients paced at 188 different LV pacing sites were investigated. Lateral LV pacing resulted in a larger %ΔLVdP/dtmax than anterior or posterior pacing (p = 0.0007). A similar trend was found for ΔQRS area (p = 0.001) but not for ΔQRS duration (p = 0.23). Pacing from the proximal electrode pair resulted in a larger %ΔLVdP/dtmax (p = 0.004), and ΔQRS area (p = 0.003) but not ΔQRS duration (p = 0.77). Within patients, correlation between ΔQRS area and %ΔLVdP/dtmax was 0.76 (median, IQR 0.35; 0.89). Conclusion: Within patients, ΔQRS area is associated with %ΔLVdP/dtmax at different LV pacing locations. Therefore, QRS area, which is an easily, noninvasively obtainable and objective parameter, may be useful to guide LV lead placement in CRT.

Keywords: cardiac resynchronization therapy; LV lead placement; QRS area; invasive hemodynamic measurements; heart failure

1. Introduction

Cardiac resynchronization therapy (CRT) has become one of the most successful treatments for heart failure. Current guidelines indicate a CRT device in patients with a reduced left ventricular (LV) systolic function in combination with electrocardiographic signs of intraventricular conduction abnormalities, presented as a wide QRS duration and the presence of an left bundle branch block (LBBB) QRS morphology [1,2].

The electrical substrate amenable to CRT is hypothesized to be delayed electrical activation of the left ventricular (LV) lateral wall, which can be measured by invasive electrophysiological examination. Vectorcardiographically determined QRS area is able to detect the electrical substrate better than QRS duration or LBBB morphology [3]. Moreover, baseline QRS area predicts echocardiographic response after CRT, and is strongly associated with clinical outcomes, including mortality [4–7].
In addition to baseline QRS area of the intrinsic rhythm, it was recently demonstrated that also reduction in QRS area after CRT is of clinical importance. A larger reduction in QRS area was associated with echocardiographic and clinical response after CRT [6–8]. Although these data were obtained using single measurements per patient, the results raised the question whether reduction in QRS area might be used to guide LV lead positioning in the individual patient.

Currently, LV lead positioning is guided by coronary venous anatomy. However, several studies were not able to show a significant difference in outcome between various anatomical lead locations [9]. At least part of these negative results may be explained by differences between patients, pointing to the need of personalization of LV lead placement. To this purpose, several approaches have been proposed, such as measurement of latest electrical (Q-LV time; ECG imaging) or mechanical (speckle tracking echocardiography, cardiac magnetic resonance) activated region, all or not in combination with localizing scar [10–14].

However, these studies use the baseline condition and do not take into account the change in activation caused by CRT. The use of the change in QRS area may have two advantages: taking into account the change in activation and the fact that this variable is easily measured. Therefore, the present study aims to investigate whether the reduction in QRS area can be used to guide LV lead placement. To this purpose, the acute hemodynamic changes during various LV lead positions per patient were studied in relation to the change in QRS area during CRT implantation.

2. Methods

2.1. Study Population

We conducted an analysis on prospectively included CRT patients from three hospitals with a class Ia or class IIa indication for CRT. The analyses were performed on the patients that were included in two previously conducted studies evaluating the acute hemodynamic effects of CRT [15,16]. All patients underwent implantation of a CRT device with a quadripolar LV lead. In the study of Zanon et al. [16], twenty-nine consecutive patients from one center (Santa Maria della Misericordia General Hospital, Rovigo, Italy) referred for CRT were included, and in the study of Salden et al. [15], twenty-seven CRT patients from two additional hospitals (Maastricht University Medical Center+ and Radboud University Medical Center, Nijmegen, The Netherlands) were included. Both studies were previously approved by their local ethics committee and were conducted in compliance with the Declaration of Helsinki.

2.2. Study Protocol and Hemodynamic Measurements

In both studies, patients underwent CRT implantation with the right ventricular lead in the (apical) septum, and the atrial lead in the right atrial appendage. In the study of Zanon et al., a telescopic approach was used for cannulation of the coronary sinus and sub cannulation of all suitable collateral veins, which allows continuous selective navigation with angiographic visualization [17]. All available veins were cannulated and then targeted with an LV quadripolar pacing lead. Paced 12-lead ECG tracings were recorded from every patient and relative change in maximum rate of rise of left ventricular (LV) pressure (%\(\Delta\frac{LVdP}{dt_{\text{max}}}\)) measurements were performed with a PressureWire Certus and PhysionMon software (St. Jude Medical Systems AB, Uppsala, Sweden). For these \(\frac{LVdP}{dt_{\text{max}}}\) measurements a 4F multipurpose catheter was inserted through a femoral or radial arterial access site and placed in a stable LV position. The AV- and VV-delays were fixed at 130 ms and 0 ms, respectively.

In the study from Salden et al., the LV lead was positioned in a suitable coronary vein on the posterolateral LV wall. In these patients, biventricular pacing measurements from a quadripolar LV lead were performed with a proximal and distal pacing configuration. At each configuration, 12-lead ECG and \(\frac{LVdP}{dt_{\text{max}}}\) measurements were taken, with the LV lead in posterolateral position. AV-delay was set 60 ms shorter than the intrinsic
PR-interval, with a maximum AV-delay of 150 ms, and the VV-delay was set at 0 ms. For the LVdP/dtmax measurements a 0.014-inch PressureWire X (Abbott, St Paul, Minnesota, MN, USA) was introduced via a 4F multipurpose catheter through a femoral artery and placed in a stable LV position.

In both studies, the average LVdP/dtmax of at least 10 beats at baseline (AAI pacing) and during pacing from each LV lead position was measured in each patient. Ventricular extrasystoles were excluded. The %ΔLVdP/dtmax was calculated as the percentual change of LVdP/dtmax with every pacing site compared to baseline.

2.3. Electrocardiographic Data

ECGs at baseline and per LV pacing location were digitally stored for offline analysis [8]. For QRS area calculations, 12-lead ECG signals were extracted from digitally stored PDF files and converted into three orthogonal VCG (X-, Y-, and Z-) leads using the Kors conversion matrix in the custom made Matlab software (Mathworks Inc.) as previously described [8]. QRS area was calculated as $(X_{area}^2 + Y_{area}^2 + Z_{area}^2)^{1/2}$ (Figure 1). QRS duration was determined using the same software. To quantify the degree of resynchronization, the absolute difference in both QRS area and QRS duration between baseline and biventricular pacing ($\Delta$QRS area and $\Delta$QRS duration) were calculated. QRS morphology was defined based on ESC 2013 criteria [18].

![Figure 1. Transformation of ECG to VCG and calculation of (Δ) QRS area. The 12-lead ECGs are mathematically converted in VCGs with the three orthogonal X-, Y-, and Z-leads using the Kors matrix. The X-, Y- and Z-leads of a patient with intrinsic rhythm and with CRT-pacing are shown. QRS area is calculated from the three orthogonal leads using the formula presented. As shown in this example, QRS area does not necessarily correlate with QRS duration. VCG = vectorcardiogram; CRT = cardiac resynchronization therapy. BiV pacing = biventricular pacing. Reprinted with permission from [8] Copyright © 2021 The Authors.](image-url)
2.4. Statistical Analysis

Statistical analysis was carried out using the IBM SPSS package, version 26 (SPSS Inc., Chicago, IL, USA) and Graphpad Prism version 9.2.0 for Windows (GraphPad Software Inc., San Diego, CA, USA). Continuous and categorical variables are reported as mean ± SD and counts (percentages), respectively. Continuous variables were compared within patients using a paired T-test. A one-way ANOVA or mixed-effects model was used when comparing more than two categories. To correct for the within-patient measurements, a Geisser–Greenhouse correction was applied. Pearson’s and Spearman’s correlation coefficient were calculated to investigate the relation between ∆QRS area and %ΔLVdP/dt_max.

3. Results
3.1. Baseline Characteristics

In 52 patients (Figure 2), ECGs and LVdP/dt_max data were available for analysis. This cohort represented a general CRT population with an age of 70 ± 9 years, of which 79% was male, and 50% had an ischemic cardiomyopathy. All patients were in NYHA functional class II or III, with a left ventricular ejection fraction (LVEF) of 29 ± 9%. Sinus rhythm was present in 71% of the patients during implantation with an average QRS duration of 169 ± 18 ms and QRS area of 108 ± 44 μVs (Table 1). LBBB was present in 67%, non-specific intraventricular conduction delay (IVCD) in 12%, right bundle branch block (RBBB) in 8%, and RV pacing in 13% of the studied patients.

Table 1. Baseline characteristics of study population.

|                          | All Patients (n = 52) |
|--------------------------|-----------------------|
| Age (y)                  | 70 ± 9                |
| Male (n, %)              | 41 (79)               |
| NYHA                     |                       |
| II (n, %)                | 28 (54)               |
| III (n, %)               | 24 (46)               |
| Ischemic CMP (n, %)      | 26 (50)               |
| Baseline LVEF (%)        | 29 ± 9                |
| Sinus rhythm (n, %)      | 37 (71)               |
| QRS duration (ms)        | 169 ± 18              |
| LBBB (n, %)              | 35 (67)               |
| IVCD (n, %)              | 6 (12)                |
| RBBB (n, %)              | 4 (8)                 |
| Upgrade from RV pacing (n, %) | 7 (13)              |
| QRS area (μVs)           | 108 ± 44              |

NYHA = New York Heart Association; CMP = cardiomyopathy; LVEF = left ventricular ejection fraction; LBBB = left bundle branch block; IVCD = non-specific intraventricular conduction delay; RBBB = right bundle branch block; RV = right ventricular.
Figure 2. Flowchart of patients. A total of 56 patients were analyzed in previous studies. Four patients in which VCG analysis was not available were excluded, bringing the number of eligible patients to 52. Patients were analyzed depending on the number of different intra-individual pacing measurements. VCG = vectorcardiogram.

3.2. ΔQRS Area, ΔQRS Duration, and %ΔLVdP/dt<sub>max</sub> at Various LV Lead Positions

Information on ΔQRS area, ΔQRS duration, and %ΔLVdP/dt<sub>max</sub> during biventricular pacing at different anatomical LV lead positions (anterior, anterolateral, lateral, posterolateral, posterior) was available in 26 patients (Figure 1). A mixed-effects statistical model showed that both QRS area and %LVdP/dt<sub>max</sub> changed significantly within each patient, both dependent on the LV pacing site (p = 0.001 and p = 0.0007, respectively, Figure 3A,C, left). ΔQRS area was significantly larger with anterolateral (−43 µVs) as compared to posterolateral (−17 µVs), and posterior (+9 µVs) LV pacing, and it was significantly larger with lateral (−48 µVs) LV pacing as compared to anterior (−13 µVs) and posterior LV pacing (Figure 3A). The results on the %ΔLVdP/dt<sub>max</sub> at various LV lead positions were in concordance with the results on ΔQRS area. The largest %ΔLVdP/dt<sub>max</sub> was found during LV lateral wall pacing (24%), with a significantly higher increase than LV anterior (12%) or posterior (11%) wall pacing (Figure 3A, right). There was no significant difference in ΔQRS duration between the different pacing locations (Figure 3B, left).
Figure 3. ∆QRS area (A), ∆QRS duration (B), and ΔLVdP/Δt\text{max} (C) with different pacing locations. Left: p-values calculated with mixed-effects analysis and Sidak’s multiple comparison test. Right: p-values calculated with paired sample T-test. * p < 0.05.
3.3. Relationship between Anatomical LV Lead Position and Largest QRS Area Reduction and Relative LVdP/dt_max Increase

In 21 patients with at least two different anatomical LV lead pacing locations, the largest ΔQRS area was achieved from the lateral pacing position in ten patients (48%), from the anterolateral position in five patients (24%), from the posterolateral wall in four patients (19%), from the anterior position in two patients (1%), and from the posterior position in one patient (0.5%). In these patients, the largest LVdP/dt_max increase was achieved from the lateral pacing position in eleven patients (52%), from the anterolateral position in six patients (29%), from the posterolateral position in four patients (19%), and from the posterior position in one patient (0.5%).

3.4. ΔQRS Area and %ΔLVdP/dt_max with Pacing from the Distal and Proximal LV Lead

From 43 patients (Figure 1), ΔQRS area and relative ΔLVdP/dt_max could be studied with LV pacing from the proximal and distal electrode pair on the quadripolar LV lead. The ΔQRS area was significantly larger with pacing from the proximal LV electrode as compared to the distal electrode (–39µVs vs. –17µVs, p = 0.0005, Figure 3A, right). In addition, ΔLVdP/dt_max was significantly larger when pacing from the proximal LV electrodes, although the difference was smaller than for ΔQRS area (18 vs. 16%, p = 0.0063, Figure 3C, right). There was no significant difference in ΔQRS duration when comparing LV pacing on the proximal versus distal electrodes (Figure 3B, right).

3.5. Relation between ΔQRS Area and ΔLVdP/dt_max

In 188 different pacing measurements, a Spearman’s correlation test found a significant association between ΔQRS area and ΔLVdP/dt_max (Rs = 0.47, p < 0.0001). In 36 out of the 43 patients (84%) with at least two different pacing measurements, %ΔLVdP/dt_max was within 5% of the largest %ΔLVdP/dt_max of that patient. Within the 21 patients with at least three different LV pacing sites, the correlation between ΔQRS area and %ΔLVdP/dt_max was determined. As shown in Figure 4, this relation varied between patients, as shown by the variation in slope and intercept between patients. However, for the vast majority of patients, correlation between ΔQRS area and %ΔLVdP/dt_max was strong (median R = 0.76, interquartile range 0.35–0.89, Figure 4).

![Figure 4](https://via.placeholder.com/150)

**Figure 4.** Plots of the relationship between ΔQRS area and ΔLVdP/dt_max in individual patients from Zanon et al. [16]. Only patients with at least three pacing measurement were plotted (n = 21). Median R and interquartile range (IQR) are displayed.
4. Discussion

4.1. Main Findings

The present study in patients with a CRT indication shows that the reduction in QRS area during biventricular pacing correlates well with acute hemodynamic improvement. LV lateral and anterolateral pacing reduced QRS area most along with maximal hemodynamic improvement. In addition, when pacing with quadrripolar LV leads, pacing proximally showed the largest reduction in QRS area and largest increase in $LVdP/dt_{max}$. Such relations were not observed for the change in QRS duration. Moreover, within patients a highly significant relation between $\Delta$QRS area and $\%\Delta LVdP/dt_{max}$ was found. These results indicate that the reduction in QRS area during biventricular pacing can be used to guide the LV lead placement in heart failure patients undergoing CRT-device implantation.

4.2. QRS Area Reduction Represents Resynchronization Better Than QRS Duration or Morphology Change

This study is the first to investigate the relationship between $\Delta$QRS area and acute hemodynamic improvement within CRT patients. The results of the current analysis support previous findings in which $\Delta$QRS area was studied in CRT registries in relation to clinical and echocardiographic outcomes. Okafor et al. found that a reduction in QRS area in combination with a reduction in QRS duration was significantly associated with long-term cardiac and total mortality, major adverse cardiac events, and ventricular arrhythmias [6]. More recently, a study from our institute showed that in a large cohort of 1299 patients, $\Delta$QRS area was independently associated with long-term survival and echocardiographic response [8]. The current analysis shows that $\Delta$QRS area also correlates with acute hemodynamic improvement during biventricular pacing at various LV pacing sites.

Our findings were also in agreement with the study of De Pooter et al., in which $\Delta$QRS area and $\Delta$QRS duration were measured in different pacing configurations and were studied in relation to acute hemodynamic response. In the study of De Pooter et al., both reduction in QRS area and QRS duration were predictive of acute hemodynamic response. Nevertheless, QRS area reduction was the best predictor [19]. More studies have investigated $\Delta$QRS duration in relation to clinical and echocardiographic outcomes. This has, however, led to mixed results. A sub study of the PROSPECT trial showed an association between QRS duration reduction and the combined endpoint of echocardiographic response and clinical improvement [20]. In the REVERSE trial, however, this association was not observed [21]. In the present study, we found that QRS duration does not change significantly with different pacing locations within a patient and could not be used to guide LV lead placement.

A probably important factor for the conflicting $\Delta$QRS duration results is the inter- and intra-observer variability in measuring QRS duration during biventricular pacing. As shown by de Pooter et al., the variability of these measurements amounted to around 20 ms, and the technique used for QRS duration measurement even influenced the association with response to CRT [22,23]. These findings suggest that an error margin for measuring QRS duration exists, and that this error margin could have consequences for the prediction of response to CRT. For QRS area, the variability is less than half of that of QRS duration [22], making QRS area a more accurate and objective measure.

The QRS area measurement combines both QRS duration and morphology. The importance of both QRS duration and morphology change has been demonstrated by Sweeney et al. in which the combination of a biventricular paced QRS fusion pattern and QRS duration reduction $\geq 25$ ms was associated with echocardiographic response to CRT [24]. Analyses based only on QRS duration are incomplete in nature. Both QRS morphology and duration are important for patient selection as indicated by the guidelines, and we believe that changes in both—reflected in QRS area—should be considered when assessing ventricular electrical resynchronization.
4.3. The Relevance of the LV Lead Position

The location where the transvenous LV lead is placed via the coronary sinus has been considered important for optimal effect of CRT. One of the earlier studies found that pacing from the lateral wall resulted in greater LVdP/dt\text{max} increase than with anterior LV pacing [25]. Other studies have shown conflicting results regarding the LV lateral wall as the optimal pacing site [26–28]. A retrospective study of 457 consecutive patients implanted with a CRT device found that patients with a final LV lateral wall lead position failed to show significant 4-year survival benefit over patients with a final non-lateral LV pacing site [29]. As proposed recently by Wouters et al. [30], findings from the present study indicate that the optimal anatomical LV pacing location does not exist, but rather that the final anatomical location of the LV lead should be individualized.

In the present study, we distinguished between five different anatomical locations: anterior, anterolateral, lateral, posterolateral, and posterior. Most patients achieved the largest ΔQRS area and ΔLVdP/dt\text{max} with a lateral and anterolateral LV pacing position. Interestingly, in this study, however, QRS area reduction was largest in two patients with anterior LV pacing and in one patient with posterior LV pacing, while acute hemodynamic change was largest with posterior pacing in one patient.

Pacing in or nearby scar tissue of patients with ischemic cardiomyopathy is an important example of unfavorable LV lead placement as it leads to worse resynchronization and outcome than pacing in viable tissue [10]. Compared to patients with a non-ischemic cardiomyopathy, CRT in patients with an ischemic cardiomyopathy led to lower reduction in QRS area, which in turn was associated with poor outcome [8]. The significant correlation between ΔQRS area and ΔLVdP/dt\text{max} indicates that QRS area can be used to individualize optimal LV lead placement and choice of most appropriate electrode on the quadripolar LV pacing lead.

4.4. Clinical Implications and Future Perspectives

QRS area has great potential for application in routine clinical care. Currently, its calculation requires a standard digital ECG and computer software to transform the ECG into VCG, resulting in an objective and accurate electrocardiographic measurement [23]. Software for automatic QRS area calculation from standard 12-lead ECGs is not yet commercially available in current clinical practice. However, similar to electrocardiographic parameters such as PR-interval and QRS duration, QRS area can also be calculated and displayed on the ECG when software becomes commercially available in the future. In addition to the current analysis on pacing location, the relation between ΔQRS area and acute hemodynamic improvement could be studied with various AV- and VV-delays in future studies.

The currently best optimization methods available are the ECG and echocardiograph. As we can conclude from aforementioned studies, there is currently no evident proof that the investigated ECG markers including QRS duration can be used for CRT optimization [20,21], or for LV lead placement for that matter. As for echocardiography—whereas its ability to detail mechanical dyssynchrony and hemodynamic surrogates provide clear potential for echocardiographic parameters in CRT optimization—studies show conflicting results and its use for CRT optimization still needs to be investigated [31]. In addition, the use of echocardiography for LV lead placement during device implantation would be impractical.

4.5. Limitations

This study assessed the relative increase in LVdP/dt\text{max} due to biventricular pacing as a marker for acute hemodynamic improvement, which has its limitations when translating the results to clinical or echocardiographic outcomes. Evidence for a relationship between acute hemodynamic response and long-term outcome is conflicting [32–36]. An explanation is that part of the therapy of resynchronization is to induce reverse remodelling, which is achieved in the long term by processes involving more than hemodynamic ones only [37].
This study has all the limitations that come with an observational cohort study. Furthermore, we were not able to systematically evaluate all pacing sites in each patient, because in the original studies the ECG and \(LVdP/dt_{\text{max}}\) measurements were not performed on all pacing sites. However, the findings from this study that QRS area reduction relates to acute hemodynamic response are in line with our previous finding that QRS area reduction is predictive of clinical and echocardiographic outcomes [8].

5. Conclusions

The present study provides evidence that the reduction in QRS area induced by biventricular pacing can be used to guide LV lead placement to its optimal pacing site. Within patients, a significant correlation was observed between \(\Delta \text{QRS area}\) and \(\Delta \text{LVdP/dt}_{\text{max}}\). In the vast majority of patients, the largest QRS area reduction coincided with the largest hemodynamic improvement.

Author Contributions: Conceptualization, K.V., F.P., A.v.S., M.A.G.; methodology, K.V., F.P., A.v.S., F.Z., L.M., J.L., S.W., E.E., F.S., M.A.G.; software, K.V., F.P., A.v.S., M.A.G.; validation, K.V., F.P., A.v.S., M.A.G.; formal analysis, M.A.G.; investigation, M.A.G.; resources, K.V., F.P., A.v.S., M.A.G.; data curation, M.A.G.; writing—original draft preparation, M.A.G.; writing—review and editing, K.V., F.P., A.v.S., F.Z., L.M., J.L., S.W., E.E., F.S., M.A.G.; visualization, F.P., A.v.S., M.A.G.; supervision, K.V., F.P., A.v.S.; project administration, K.V., F.P., A.v.S., M.A.G.; funding acquisition, K.V., F.P. All authors have read and agreed to the published version of the manuscript.

Funding: A part of the study of Salden et al. was financially supported by Medtronic (Minneapolis, Minnesota).

Institutional Review Board Statement: Ethical review and approval were waived for this study, due to the retrospective nature of the investigation, involving data that were already collected in two previously conducted studies, both being approved by their local ethics committee at the time of the data collection and conducted in accordance with the Declaration of Helsinki.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author (M.G.) on reasonable request. The data are not publicly available due to their containing information that could compromise the privacy of research participants.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Glikson, M.; Nielsen, J.C.; Kronborg, M.B.; Michowitz, Y.; Auricchio, A.; Barbash, I.M.; Barrabés, J.A.; Boriani, G.; Braunischweig, F.; Brignole, M.; et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur. Heart J. 2021, 42, 3427–3520. [CrossRef] [PubMed]
2. Tracy, C.M.; Epstein, A.E.; Darbar, D.; Dimarco, J.P.; Dunbar, S.B.; Estes, N.A.M.; Ferguson, T.B.; Hammill, S.C.; Karasik, P.E.; Link, M.S.; et al. 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2012, 9, 1737–1753. [CrossRef] [PubMed]
3. Rad, M.M.; Wijnjens, G.W.; Engels, E.B.; Blaauw, Y.; Luermans, J.G.; Pison, L.; Crijns, H.J.; Prinzen, F.W.; Verwooy, K. Vector-cardiographic QRS area identifies delayed left ventricular lateral wall activation determined by electroanatomic mapping in candidates for cardiac resynchronization therapy. Heart Rhythm. 2016, 13, 217–225. [CrossRef]
4. Maass, A.H.; Verwooy, K.; Cramer, M.J.; Vos, M.A.; Rienstra, M.; Van Gelder, I.C.; MARC Investigators. Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: Results from the MARC study—Authors reply. Europace 2018, 20, 393. [CrossRef]
5. van Stipdonk, A.M.; ter Horst, I.; Kloosterman, M.; Engels, E.B.; Rienstra, M.; Crijns, H.J.; Vos, M.A.; van Gelder, I.C.; Prinzen, F.W.; Meine, M.; et al. QRS Area Is a Strong Determinant of Outcome in Cardiac Resynchronization Therapy. Circ. Arrhythm. Electrophysiol. 2018, 11, e006497. [CrossRef] [PubMed]
6. Okafor, O.; Zegard, A.; van Dam, P.; Stegemann, B.; Qiu, T.; Marshall, H.; Leyva, F. Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias. J. Am. Heart Assoc. 2019, 8, e013539. [CrossRef]
7. Emerek, K.; Friedman, D.J.; Sørensen, P.L.; Hansen, S.M.; Larsen, J.M.; Røsseth, J.M.; Thøgersen, A.M.; Graff, C.; Kisslo, J.; Søgaard, P.; et al. Vectorcardiographic QRS area is associated with long-term outcome after cardiac resynchronization therapy. Heart Rhythm. 2019, 16, 213–219. [CrossRef] [PubMed]

8. Ghossein, M.A.; van Stipdonk, A.M.W.; Plesinger, F.; Kloosterman, M.; Wouters, P.C.; Salden, O.A.E.; Meine, M.; Maass, A.H.; Prinzen, F.W.; Vernooy, K. Reduction in the QRS area after cardiac resynchronization therapy is associated with survival and echocardiographic response. J. Cardiovasc. Electrophysiol. 2021, 32, 813–822. [CrossRef]

9. Leiva, F.; Zegard, A.; Taylor, R.J.; Foley, P.W.X.; Umar, F.; Patel, K.; Panting, J.; van Dam, P.; Prinzen, F.W.; Marshall, H.; et al. Long-Term Outcomes of Cardiac Resynchronization Therapy Using Apical Versus Nonapical Left Ventricular Pacing. J. Am. Heart Assoc. 2018, 7, e005808. [CrossRef] [PubMed]

10. Leyva, F.; Claridge, S.; Vernooy, K.; Engels, E.B.; Razavi, R.; Rinaldi, C.A.; Chen, Z.; Prinzen, F.W. Relationship between vectorcardiographic QRS area, myocardial scar quantification, and response to cardiac resynchronization therapy. J. Electrocardiol. 2018, 51, 457–463. [CrossRef]

11. Varma, N.; Ghanem, R.; jia, P. Optimization of cardiac resynchronisation therapy: LV Lead position, qLV, or paced effects? Europace 2019, 21, 360. [CrossRef] [PubMed]

12. van Everdingen, W.M.; Zweerink, A.; Cramer, M.J.; Dooevendans, P.A.; Nguyen, U.C.; van Rossum, A.C.; Prinzen, F.W.; Vernooy, K.; Allaart, C.P.; Meine, M. Can We Use the Intrinsic Left Ventricular Delay (QLV) to Optimize the Pacing Configuration for Cardiac Resynchronization Therapy with a Quadrupolar Left Ventricular Lead? Circ. Arrhythm. Electrophysiol. 2018, 11, e005912. [CrossRef] [PubMed]

13. Saba, S.; Marek, J.; Schwartzman, D.; Jain, S.; Adelstein, E.; White, P.; Oyenuga, O.A.; Onishi, T.; Soman, P.; Gorcsan, J., III. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: Results of the Speckle Tracking Assisted Resynchronization Therapy for Electrode Region trial. Circ. Heart Fail. 2013, 6, 427–434. [CrossRef]

14. Salden, O.A.E.; Broek, H.T.V.D.; van Everdingen, W.; Hoesein, F.A.A.M.; Doevendans, P.A.; Cramer, M.J.; Tuinenburg, A.E.; Leufkens, P.; van Slochteren, F.J.; et al. Multimodality imaging for real-time image-guided left ventricular lead placement during cardiac resynchronization therapy implantations. Int. J. Cardiovasc. Imaging 2019, 35, 1327–1337. [CrossRef] [PubMed]

15. Salden, F.C.; Westra, S.W.; Weijs, B.; Engels, E.B.; Heckman, L.I.; Janssen, M.H.; Clerx, K.J.; Cornelussen, R.; et al. Short-Term Hemodynamic and Electrophysiological Effects of Cardiac Resynchronization by Left Ventricular Septal Pacing. J. Am. Coll. Cardiol. 2020, 75, 347–359. [CrossRef] [PubMed]

16. Zanon, F.; Baracca, E.; Pastore, G.; Marcatroni, L.; Fraccaro, C.; Lanza, D.; Picariello, C.; Aggio, S.; Roncon, L.; Dell’Avvocata, F.; et al. Multipoint pacing by a left ventricular quadripolar lead improves the acute hemodynamic response to CRT compared with conventional biventricular pacing at any site. Heart Rhythm. 2015, 12, 975–981. [CrossRef] [PubMed]

17. Zanon, F.; Baracca, E.; Pastore, G.; Aggio, S.; Rigatelli, G.; Dondina, C.; Marras, G.; Braggioni, G.; Boaretto, G.; Cardiaoli, P.; et al. Implantation of left ventricular leads using a telescopic catheter system. Pacing Clin. Electrophysiol. 2006, 29, 1266–1272. [CrossRef] [PubMed]

18. Brignole, M.; Auricchio, A.; Baron-Esquivias, G.; Bordachar, P.; Boriani, G.; Breithardt, O.-A.; Cleland, J.G.F.; Dehario, J.-C.; Delgado, V.; Elliott, P.M.; et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur. Heart J. 2013, 34, 2281–2329. [PubMed]

19. De Pooter, J.; El Haddad, M.; De Buyzere, M.; Aranda, H.A.; Cornilussen, R.; Stegemann, B.; Rinaldi, C.A.; Sterlinski, M.; Sokal, A.; Francis, D.P.; et al. Biventricular Paced QRS Area Predicts Acute Hemodynamic CRT Response Better Than QRS Duration or QRS Amplitudes. J. Cardiovasc. Electrophysiol. 2017, 28, 192–200. [CrossRef] [PubMed]

20. Hsing, J.M.; Selzman, K.A.; Leclercq, C.; Pires, L.A.; McLaughlin, M.G.; McRae, S.E.; Peterson, B.J.; Zimetbaum, P.J. Paced left ventricular QRS width and ECG parameters predict outcomes after cardiac resynchronization therapy: PROSPECT-ECG substudy. Circ. Arrhythm. Electrophysiol. 2011, 4, 851–857. [CrossRef] [PubMed]

21. Gold, M.R.; Thebault, C.; Linde, C.; Abraham, W.T.; Gerrits, B.; Ghio, S.; Sutton, M.S.J.; Daubert, J.-C. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: Results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation 2012, 126, 822–829. [CrossRef]

22. De Pooter, J.; El Haddad, M.; Timmers, L.; Van Heuverswyn, F.; Jordens, L.; Duyschaever, M.; Stroobandt, R. Different Methods to Measure QRS Duration in CRT Patients: Impact on the Predictive Value of QRS Duration Parameters. Ann. Noninvasive Electrocardiol. 2016, 21, 305–315. [CrossRef] [PubMed]

23. De Pooter, J.; El Haddad, M.; Stroobandt, R.; De Buyzere, M.; Timmermans, F. Accuracy of computer-calculated and manual QRS duration assessments: Clinical implications to select candidates for cardiac resynchronization therapy. Int. J. Cardiol. 2017, 236, 276–282. [CrossRef] [PubMed]

24. Sweeney, M.O.; Hellkamp, A.S.; van Bommel, R.J.; Schali, M.J.; Borleffs, C.J.; Bax, J.J. QRS fusion complex analysis using wave interference to predict reverse remodeling during cardiac resynchronization therapy. Heart Rhythm. 2014, 11, 806–813. [CrossRef] [PubMed]

25. Butter, C.; Auricchio, A.; Stellbrink, C.; Fleck, E.; Ding, J.; Yu, Y.; Huvelle, E.; Spinelli, J. Effect of resynchronization therapy stimulation site on the systolic function of heart failure patients. Circulation 2001, 104, 3026–3029. [CrossRef]
26. Macias, A.; Gavira, J.J.; Castano, S.; Alegria, E.; Garcia-Bolao, I. Left ventricular pacing site in cardiac resynchronization therapy: Clinical follow-up and predictors of failed lateral implant. *Eur. J. Heart Fail.* 2008, 10, 421–427. [CrossRef]

27. Kronborg, M.B.; Albertsen, A.E.; Nielsen, J.C.; Mortensen, P.T. Long-term clinical outcome and left ventricular lead position in cardiac resynchronization therapy. *Europace* 2009, 11, 1177–1182. [CrossRef]

28. Wilton, S.B.; Shibata, M.A.; Søndergaard, R.; Cowan, K.; Semeniuk, L.; Exner, D.V. Relationship between left ventricular lead position using a simple radiographic classification scheme and long-term outcome with resynchronization therapy. *J. Interv. Card. Electrophysiol.* 2008, 23, 219–227. [CrossRef] [PubMed]

29. Dong, Y.-X.; Powell, B.D.; Asirvatham, S.J.; Friedman, P.A.; Rea, R.F.; Webster, T.L.; Brooke, K.L.; Hodge, D.O.; Wiste, H.J.; Yang, Y.-Z.; et al. Left ventricular lead position for cardiac resynchronization: A comprehensive cinegraphic, echocardiographic, clinical, and survival analysis. *Europace* 2012, 14, 1139–1147. [CrossRef] [PubMed]

30. Wouters, P.C.; Vernooy, K.; Cramer, M.J.; Prinzen, F.W.; Meine, M. Optimizing lead placement for pacing in dyssynchronous heart failure: The patient in the lead. *Heart Rhythm.* 2021, 18, 1024–1032. [CrossRef] [PubMed]

31. Spartalis, M.; Tzatzaki, E.; Spartalis, E.; Damaskos, C.; Athanasiou, A.; Livianis, E.; Voudris, V. The Role of Echocardiography in the Optimization of Cardiac Resynchronization Therapy: Current Evidence and Future Perspectives. *Open Cardiovasc. Med. J.* 2017, 11, 133–145. [CrossRef] [PubMed]

32. Duckett, S.G.; Ginks, M.; Shetty, A.; Bostock, J.; Gill, J.S.; Hamid, S.; Kapetanakis, S.; Cunliffe, E.; Razavi, R.; Carr-White, G.; et al. Invasive acute hemodynamic response to guide left ventricular lead implantation predicts chronic remodeling in patients undergoing cardiac resynchronization therapy. *J. Am. Coll. Cardiol.* 2011, 58, 1128–1136. [CrossRef] [PubMed]

33. Stellbrink, C.; Breithardt, O.-A.; Franke, A.; Sack, S.; Bakker, P.; Auricchio, A.; Pochet, T.; Salo, R.; Kramer, A.; Spinelli, J. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. *J. Am. Coll. Cardiol.* 2001, 38, 1957–1963. [CrossRef]

34. Mullens, W.; Verga, T.; Grimm, R.A.; Starling, R.C.; Wilkoff, B.L.; Tang, W.H.W. Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. *J. Am. Coll. Cardiol.* 2009, 53, 600–607. [CrossRef] [PubMed]

35. Bogaard, M.D.; Houthuizen, P.; Bracke, F.A.; Doevendans, P.A.; Prinzen, F.W.; Meine, M.; van Gelder, B.M. Baseline left ventricular dP/dtmax rather than the acute improvement in dP/dtmax predicts clinical outcome in patients with cardiac resynchronization therapy. *Eur. J. Heart Fail.* 2011, 13, 1126–1132. [CrossRef] [PubMed]

36. Suzuki, H.; Shimano, M.; Yoshida, Y.; Inden, Y.; Muramatsu, T.; Tsuji, Y.; Tsuboi, N.; Hirayama, H.; Shibata, R.; Murohara, T. Maximum derivative of left ventricular pressure predicts cardiac mortality after cardiac resynchronization therapy. *Clin. Cardiol.* 2010, 33, E18–E23. [CrossRef] [PubMed]

37. Prinzen, F.W.; Auricchio, A. The “missing” link between acute hemodynamic effect and clinical response. *J. Cardiovasc. Transl. Res.* 2012, 5, 188–195. [CrossRef] [PubMed]